A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

Phase 3

Recruiting

• Conditions: Carcinoma, Non-Small-Cell Lung
• Interventions: Drug: BAT3306; Drug: EU-Keytruda®; Drug: US-Keytruda®; Drug: Pemetrexed; Drug: Carboplatin

• Registration Number: NCT06280196
• Lead Sponsor: Bio-Thera Solutions

Brief Summary

To compare the pairwise PK similarities between BAT3306, EU-Keytruda, and US-Keytruda, all administered with pemetrexed and carboplatin.

Detailed Description

This is a multi-center, double-blind, randomized study that includes PK and clinical equivalence comparisons, aimed at comparing BAT3306 with Keytruda® in previously untreated participants with Stage IV nsNSCLC.

Study Timeline

• Study First Submitted: 2024-02-04
• Study First Submitted QC: 2024-02-26
• Study First Posted: 2024-02-28
• Study Start: 2024-07-19
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-26
• Last Update Posted: 2024-12-31
• Primary Completion: 2027-07-30
• Study Completion: 2028-10-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 676

Inclusion Criteria

• Participants are eligible to be included in the study only if all the following criteria are met:

  1. Male or female, age ≥18 years on the day of signing informed consent.
  2. Participants are able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures.
  3. Life expectancy ≥3 months, per the investigator's evaluation.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
  5. Histologically/cytologically confirmed diagnosis of Stage IV (AJCC 8th edition) nsNSCLC.
  6. Tumors without EGFR mutation/ROS1 rearrangement /ALK rearrangement.

Exclusion Criteria

• Participant must be excluded from participating in the study if the participant:

  1. Is pregnant or a nursing female.

  2. Has predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the participant is ineligible.

  3. Is currently participating and receiving an investigational agent or has participated in a study of an investigational agent and received an investigational agent or used an investigational device within 4 weeks prior to administration of the first dose of study intervention.

  4. Before the first dose of study intervention:

     • Had received prior systemic antineoplastic chemotherapy and targeted, biological therapy
     • Had prior treatment with any other anti-PD-1, PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against TIGIT, IDO, PD-L1, CTLA-4, and LAG3.
     • Has participated in any other BAT3306 study and has been treated with BAT3306.
     • Had major surgery <3 weeks prior to first dose
     • Received radiation therapy to the lung that is > 30 Gy within 6 months of the first dose of study intervention.
     • Completed palliative radiotherapy within 14 days of the first dose of study intervention.

  5. Is expected to require any other form of antineoplastic therapy while participating in the study. and so on

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BAT3306	BAT3306	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
EU-Keytruda® arm	EU-Keytruda®	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
US-Keytruda® arm	US-Keytruda®	25 mg/mL concentrate for solution for infusion. 200 mg on Day 1 of each 21-day cycle
BAT3306	Pemetrexed	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
BAT3306	Carboplatin	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
EU-Keytruda® arm	Pemetrexed	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
EU-Keytruda® arm	Carboplatin	25 mg/mL concentrate for solution for infusion.200 mg on Day 1 of each 21-day cycle
US-Keytruda® arm	Pemetrexed	25 mg/mL concentrate for solution for infusion. 200 mg on Day 1 of each 21-day cycle
US-Keytruda® arm	Carboplatin	25 mg/mL concentrate for solution for infusion. 200 mg on Day 1 of each 21-day cycle

Primary Outcome Measures

Name	Time	Method
clinical equivalence	Week 3,5,7,9,12,15,EOT	To compare the efficacy of BAT3306 and pooled EU-Keytruda® and US-Keytruda® given with chemotherapy as first line treatment using ORR assessed by BIRC to show clinical equivalence in participants with nsNSCLC. Confirmed best overall tumor response rate as assessed by BIRC according to RECIST Version 1.1 (tumor assessments after initiation of a new anti-cancer treatment are excluded)

Secondary Outcome Measures

Name	Time	Method
safety of BAT3306	From signed ICF to 90days after the last drug administration	The Investigator and any qualified designees are responsible for detecting, documenting, and reporting events that meet the definition of an AE or SAE and remain responsible for following up AE that are serious, considered related to the study intervention or the study, or that caused the participant to discontinue the study.

Trial Locations

Locations (1)

Union Hospital Tongji Medical College Huazhong University of Science & Technology; 🇨🇳 Wuhan, Hubei, China